Stopping mycophenolate in older kidney transplant recipients
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests whether some older adults who have had a kidney transplant for more than a year can safely stop taking one of their anti-rejection medicines (mycophenolate mofetil, or MMF) instead of staying on it long-term. If you qualify, you may be able to reduce your daily pill burden while keeping your new kidney safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 61 years old or older.
- You had your kidney transplant more than 12 months ago.
- You take tacrolimus and have been on a stable dose for at least 3 months.
- You have not had a rejection episode in the last 6 months and are not at high immunologic risk.
- You do not have active cancer (except non-melanoma skin cancer), serious infection, or BK virus in your blood or kidney.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study tests if switching to an extended-release form of your anti-rejection medication (tacrolimus) helps protect memory and thinking skills. It is for older adults who have had a kidney transplant at least one year ago.
This study looks at whether it is safe to stop or reduce anti-rejection medicines in children who have had a liver transplant for at least 4 years and are doing well. The goal is to see if they can live without these medicines and their side effects.
This trial tests a mycophenolate-based therapy for kidney transplant recipients who have no HLA-DQ mismatch. If you had your first kidney transplant 3-12 months ago without DQ mismatch and are on standard immunosuppressants, you may qualify.
Hear when a new Kidney Transplant Recipient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.